Get started
Work

Supplementary Figure S1 from Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent

Year: 2023
Type: supplementary-materials
Abstract: CONSORT diagram for the phase I/II trial of everolimus with and without BNC105P
DOI: 10.1158/1535-7163.22522713
Authors: Eddy S. Yang, Amin H. Nassar, Elio Adib, Opeyemi A. Jegede, Sarah Abou Alaiwi, Deborah L. Della Manna, David A. Braun, Mahsa Zarei, Heng Du, Sumanta K. Pal, Gurudatta Naik, Guru P. Sonpavde
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4362529870
Cites:
Cited by:
Related to: 10